Randomized Trialhigh evidence
Tolerability, safety, and efficacy of atogepant versus topiramate in adults with migraine (TEMPLE): a randomised, head-to-head, phase 3b trial.
The Lancet. Neurology·July 23, 2026·PMID 42492556
Why it mattersDirect comparative evidence between a CGRP receptor antagonist and a conventional oral preventive has been lacking. These data help clinicians weigh tolerability and efficacy when selecting first-line or step-therapy options for migraine prevention.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled